Ruxolitinib Clinical and Microbiological Implications and Possible Association with B Cell Lymphoma

Autor: OKAY, Müfide, SAĞLAM, Arzu, MALKAN, Ümit Yavuz, BÜYÜKAŞIK, Yahya, AKSU, Salih, SAYINALP, Nilgün, HAZNEDAROĞLU, İbrahim Celalettin
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Volume: 3, Issue: 3 134-141
Çukurova Anestezi ve Cerrahi Bilimler Dergisi
ISSN: 2667-498X
Popis: IntroductionRuxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor for the treatment with primary myelofibrosis (PMF), post–polycythemia MF (PPVMF), and post–essential thrombocythemia MF (PETMF) for diseaserelated splenomegaly or symptoms in adult patients. Ruxolitinib is effective treatment choice for myelofibrosis. But ruxolitinib has some adverse event, hematologic and nonhematologic. In this study, we wanted to present the results of our patients using ruxolitinib. Materials and MethodsTotal 40 patients data were retrospectively analyzed. Categorical and continuous data were expressed as ratio (%) and median (range). Overall survival (OS) is taken as end-points of this study. ResultsThe total number of patients was 40. 4 patient received ruxolitinib for cGVHD after allogeneic stem cell tranplantation. The total number of patients who analyzed was 28. The median age of patients was 54 years (35-78). Median ruxolitinib treatment duration was 383 days (37-1596 days). After ruxolitinib, median platelet, hemoglobin, neutrophil nadir durations were 46 days (0-546), 40 days (14-218days) and 112 days (16-546days), respectively. The median nadir hemoglobin and platelet level were 8.3 g/dl (5 g/dl -15 g/dl) and 147.5103/µl (29103/µl -589103/µl), respectively. The median follow up was 1291 days (40 -8053 days). The 5-year OS rate was 60.6% and 90% in hemoglobine and platelet recovery time
Databáze: OpenAIRE
Externí odkaz: